Our History

2000

WuXi PharmaTech was founded to support innovators in discovering, developing and commercializing new medicines and healthcare products for patients

2001

Launched synthetic chemistry services

2003

Began manufacturing process development services

2004

Initiated manufacturing services for research and development

2005

Started bio-analytical services

2007

Began offering toxicology and formulation services

Listed on the New York Stock Exchange

2008

Acquired AppTec Laboratory Services, after which the company was renamed WuXi AppTec

2011

Acquired Medkey, expanding to clinical development and registration services

First annual WuXi Global Forum held in San Francisco alongside the J.P. Morgan Healthcare Conference

2014

Acquired XenoBiotic Laboratories, adding to the company’s research capabilities

2015

Expanded medical device testing services

Delisted from the New York Stock Exchange

2016

Acquired CRELUX, enhancing WuXi AppTec's structure-based drug discovery capabilities

2017

Acquired HD Biosciences, strengthening biology R&D capacity and capability

Acquired ResearchPoint Global, expanding U.S. clinical research capabilities

2018

Listed on Shanghai Exchange (603259.SH)

Listed on Hong Kong Exchange (2359.HK)

2019

Acquired Pharmapace, to enhance biometrics services for clinical development

2021

Purchased Bristol Myers Squibb manufacturing facility in Couvet, Switzerland

Acquired OXGENE to further strengthen cell and gene therapy service offerings for global customers

WuXi AppTec